CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure

Schaub, Malte; Walker, Britta; Sauter, Martina; Muenzer, Patrick; Gramlich, Michael; Mueller, Karin; Geisler, Tobias; Läng, Florian; Klingel, Karin; Kandolf, Reinhard; Bigalke, Boris; Gawaz, Meinrad; Zuern, Christine S.

doi:10.1016/j.ijcard.2014.08.033

Cited by 26 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Soluble CXCL16 has been demonstrated to be a significant predictor of mortality in patients with either acute coronary syndrome or ischemic stroke [6,7]. Moreover, tissue CXCL16 expression has been found to be enhanced in inflammatory cardiomyopathy and to better predict mortality compared with other traditional cardiovascular risk factors in patients with heart failure who are undergoing endomyocardial biopsy [8]. The pathogenic role of CXCL16 in cardiovascular injury was further confirmed by Laugsand et al [9] who demonstrated that soluble CXCL16 was associated with the risk of myocardial infarction in a large general population without CVD.…”

Section: Introductionmentioning

confidence: 99%

Interaction of Soluble CXC Ligand 16 and Cardiac Injury Markers in Hemodialysis Patients

Liu

Wang²,

Wei³

et al. 2017

Am J Nephrol

View full text Add to dashboard Cite

Background: Recent data suggest that there is a pathogenic role for CXC ligand 16 (CXCL16) in cardiovascular diseases. Little is known about circulating CXCL16 in patients with kidney dysfunction. We explored the relationships of plasma CXCL16 with cardiac injury markers in a group of dialysis patients. Methods: Plasma CXCL16 and C-reactive protein (CRP) were measured in 366 patients who were on maintenance hemodialysis. Cardiac injury was evaluated via measurements of the circulating B-type natriuretic peptide (BNP), N-terminal prohormone of brain natriuretic peptide (NT proBNP), Troponin I (TnI), and Troponin T (TnT). Sixty healthy subjects who were frequency matched with the patients on the basis of age and gender were recruited as healthy controls. Results: The mean age of the patients was 52.5 ± 12.1 years and 56.3% were male. Circulating CXCL16 was significantly higher in the patients than in the controls (patients vs. controls: 477.3 (367.0-647.1) pg/mL vs. 229.5 (203.8-254.5) pg/mL; p < 0.001). The log-transformed (log-) CXCL16 level was correlated with all 4 cardiac markers (log-BNP, log-NTproBNP, log-TnI, and log-TnT) with high levels of significance (all p < 0.001), even after extensive controls for the covariates. In contrast, CRP was correlated only with BNP (marginally) and NT proBNP and was not correlated with troponins. Conclusion: We showed, for the first time, highly significant relationships of circulating CXCL16 level with cardiac injury markers in dialysis patients. Our data suggest that circulating CXCL16 is possibly involved in the pathological process of cardiovascular damage in dialysis patients and may serve as a therapeutic target for cardiac protection in these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction of Soluble CXC Ligand 16 and Cardiac Injury Markers in Hemodialysis Patients

Liu

Wang²,

Wei³

et al. 2017

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…The relationship between the anti-inflammatory effect of steroid therapy and functional recovery remains unknown [38,39]. Nevertheless, the present data Fig.…”

Section: Quantitated Myocardial Fdg Uptake As a Monitoring Tool For Smentioning

confidence: 58%

Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis

Yokoyama

Miyagawa

Okayama

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…Ein schlechteres Outcome konnte hier ausschließlich für Patienten mit lymphozytärer im Vergleich zur eosinophilen Myokarditis sowie für Patienten mit histopathologischem Fibrosenachweis belegt werden. Zur Bewertung der prognostischen Relevanz neuer Parameter, wie beispielsweise des Nachweises des Chemokins CXCL16 [48], sind weitere Studien erforderlich. …”

Section: Prognostische Relevanz Der Endomyokardbiopsieunclassified

Myokarditis in der Differenzialdiagnose von Kardiomyopathien

Besler

Schuler

Lurz

2015

Herz

View full text Add to dashboard Cite

Myocarditis is an inflammatory disease of the heart muscle commonly caused by viral pathogens. Dilated cardiomyopathy is a major long-term sequela of myocarditis and at least in part related to post-viral immune-mediated responses. Establishing a diagnosis of myocarditis represents a major challenge because of the variable clinical picture and the lack of readily available, non-invasive diagnostic tests. In recent years, cardiac magnetic resonance imaging (cMRI) has emerged as a promising additional diagnostic tool in patients with suspected myocarditis: cMRI not only provides important insights into structural and functional abnormalities of the heart but relevant tissue pathologies can also be visualized. The diagnostic accuracy of three tissue criteria, i.e. the edema ratio, early gadolinium enhancement ratio and late gadolinium enhancement, has been characterized in several studies. Endomyocardial biopsy (EMB) is widely considered to be the reference standard for diagnosis of myocarditis. Although limited by sampling error, EMB is the only diagnostic procedure that can be used to confirm myocarditis. Laboratory analyses of EMB may provide information about specific causes of myocarditis and are, at least in part, of prognostic relevance. In a subset of patients the results of EMB may guide therapeutic decision-making. Additional efforts are needed in cardiac imaging, molecular characterization of EMB and evaluation of serum biomarkers to improve the diagnostic work-up in patients with suspected myocarditis and to identify potential novel targets for a cause-specific therapy of myocarditis.

show abstract

CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure

Cited by 26 publications

References 48 publications

Interaction of Soluble CXC Ligand 16 and Cardiac Injury Markers in Hemodialysis Patients

Interaction of Soluble CXC Ligand 16 and Cardiac Injury Markers in Hemodialysis Patients

Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis

Myokarditis in der Differenzialdiagnose von Kardiomyopathien

Contact Info

Product

Resources

About